NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Novo Nordisk lost an intense bidding war against Pfizer for U.S. biotech firm Metsera. CNBC takes a look at what the options ...

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...